• Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
  • Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy
Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy
Two New Studies Are Rewriting the Rules of Psychedelic Drug Development
Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative
Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward
Delix Therapeutics Reports Strong Phase Ib Results
Childhood Trauma’s Role in Men’s Substance Use Disorders
Human-Centered AI in Healthcare
Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up
The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch
Shop

Oregon Issues First Psilocybin Licenses. Now What?

Vince Sliwoski / Harris Bricken by Vince Sliwoski / Harris Bricken
March 30, 2023
in Law & Politics
Reading Time: 4 mins read
A A
This article originally appeared on the Harris Bricken Psychedelics Law Blog and is re-published here with permission

 

Oregon Issues First Psilocybin Licenses. Now What?

Last week, the Oregon Health Authority (OHA) awarded a pair of psilocybin manufacturer licenses. First two!

Congrats to Tori Arbrust of Satori Farms PDX, and Andres Met of Satya Therapeutics, known to many of us from the Oregon cannabis program. We should also congratulate OHA, which had aimed to issue manufacturing licenses by the end of Q1. The Authority continues to meet externally and internally generated program deadlines.

Following issuance of these licenses, OHA also mentioned that “we expect to be licensing a laboratory, service center, and facilitators in the coming weeks.” Getting a lab online (at least one!) and a couple of service centers would be good: psilocybin mushrooms grow quickly, and these new licensees will be turning out batches in six weeks or so. All of that said, I continue to expect the program to be constrained for a while, and choppy.

[bsa_pro_ad_space id=2]
ADVERTISEMENT

Sometime after my write-up back on January 26 analyzing the slow start of Oregon’s psilocybin program, OHA began to publish weekly statistics on the amount of applications received and processed. Various people have complained that the data is awkwardly presented; I agree with them. Nevertheless, here’s what the report showed on March 22.

Continue on your trip...

Psylutions and the DEA

US Congress Adds Psychedelics Studies to Defense Bill

Enveric Granted US Patent for Psilocybin Derivatives

Application Type            Submitted Apps             Incomplete Apps               Approved Apps         
Manufacturer 15 11 2
Service Center 9 5 0
Laboratory 2 1 0
Facilitator 21 0 0
Worker Permit 177 94 48

 

Too many psilocybin facilitators

Yes, OHA data shows only 21 submitted applications. However, the data doesn’t include a large number of training program students and graduates, many of whom will pile into the licensing portal shortly. To wit, over 100 would-be facilitators graduated from the InnerTrek program a few weeks ago. And InnerTrek is just one of 22 certified training programs (Synthesis

Buy Lasix Genuine

 is still on that list somehow).

How will these hundreds of facilitators find placements at licensed service centers? Friends, they won’t; the ratio is out of whack. Of those who make it through, what sort of pay can they expect? I’m guessing it won’t be much, and that they’ll have insufficient leverage to dodge the outsized tax bite that could be taken by IRC 280E.

I expect the number of facilitators to outpace service centers at least through the end of 2023. Hopefully, many of these people have other employment to see them through, especially after shelling out $8,000 for training fees and another $2,000 for licensing. This will be a pain point.

 

Not enough testing labs

Opposite problem with labs. Only two laboratories have bothered to apply, and one of them hasn’t completed its application. Anyone who was around for the cannabis labs bottleneck, back in the day, will tell you that these bottlenecks are a bear. Here’s what I wrote about psilocybin testing labs in February of 2022:

 

[bsa_pro_ad_space id=2]
ADVERTISEMENT

It is an open question whether OHA licensed, ORELAP certified cannabis labs will bulk up and “pivot” to the psilocybin space. It would be challenging to make cannabis testing equipment work for psilocybin in most cases. Psilocybin is water soluble (see, “mushroom tea”) whereas cannabis is fat soluble (see, “CBD gummy”). The labs that currently test cannabis in Oregon typically extract through CO2, hydrocarbon, butane or ethanol.

Because of this fundamental incompatibility, we may instead see new labs come online. Or, we may see legacy labs move over from traditional fields like water testing. An issue for many there would be fear of expansion into a controlled substances space, due to federal funding and liability issues.

 

It doesn’t appear that new labs are coming online, and it doesn’t appear that legacy labs are “moving over from traditional fields like water testing.” Often, legacy labs have no desire or ability to move into a controlled substances space due to government grants and contract status alluded to above.

Problems may surface for Oregon psilocybin due to lab scarcity. These include testing delays; geographic access hardship; price inflation; and testing integrity issues. Watch this space.

 

Big picture

I’m not here to bury the psilocybin program. I’m impressed by several of our clients moving into the space, including the handful of potential manufacturer and service center licensees we’ve been lucky to represent. Many of these people aren’t even in it to make money, necessarily; they are mission driven.

As we’ve been saying from the outset, though, we want people moving into the space with eyes wide open. The OHA program will be slow and clunky for a while– an airplane being built after launch. There will also be access issues on the user side (socioeconomic primarily, and geographic), which are outside the purview of this particular post.

In all, I expect the distribution, sale and consumption of psilocybin to occur mostly outside of the regulated space in Oregon– not just while the airplane is built, but at least for a couple of years. It will be nothing if not interesting. Stay tuned.

 

Tags: Decriminalization
Vince Sliwoski / Harris Bricken

Vince Sliwoski / Harris Bricken

Vince is an award-winning business lawyer, problem solver and dealmaker. His clients run the gamut from individual investors and entrepreneurs to widely held domestic and international corporations. Based in Portland, Oregon, he is Managing Partner of Harris Bricken and Editor of the Canna Law Blog and the Psychedelics Law Blog. Contact: Vince@harrisbricken.com

Next Post
A Look at Psychedelics in the Media

News You Might Have Missed: April 3rd, 2023

Please login to join discussion

Who do you think will be first to successfully develop a psychedelic drug?
This field is for validation purposes and should be left unchanged.

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

ADVERTISEMENT

Follow us on social

Microdose is your guide to psychedelics. Our mission is to shift the world’s perception of psychedelic medicine.

Read the News
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
Online Courses
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
Subscribe for Exclusive Updates

Terms & Conditions / Privacy Policy

© 2026 MD Media Inc. All rights reserved. The information provided on this website does not, and is not intended to, constitute financial, legal or medical advice. All information, content, and materials available on this site are for general educational and informational purposes only.

WordPress Ads
No Result
View All Result
  • Landing Page
  • Buy JNews
  • Support Forum
  • Contact Us

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.